Peptide Therapy in 2026: The Updated Complete Guide to BPC-157, GHRH/GHRP, and the Latest Clinical Protocols

Five years ago, if you mentioned peptide therapy to your primary care provider, you probably got a blank stare. The conversation lived in bodybuilding forums, biohacking podcasts, and the occasional concierge longevity clinic. Today, in 2026, peptides have moved firmly into the mainstream of integrative and functional medicine. Patients walk into our clinics asking specifically for BPC-157, ipamorelin, tesamorelin, and a half-dozen others by name. Cosmetic dermatologists, sports medicine practices, longevity clinics, and primary care offices all offer some form of peptide protocol.

That mainstreaming has been a good thing in many ways. It has put powerful tools into the hands of physicians who can use them carefully. It has driven research, surfaced safety data, and created a much more sophisticated patient base. But the rapid growth has also come with real friction. The FDA's regulatory posture toward compounded peptides has shifted significantly between 2023 and 2026. Some products that used to be readily available are now harder to source legitimately. A flood of unregulated online "research peptide" vendors has filled gaps left by the legitimate compounding market, exposing patients to products of unknown identity, purity, and sterility.

This guide is our 2026 update. It is intended to do two things at once: give you a clinically grounded explanation of how the peptide families we use actually work, and tell you the truth about what is FDA-approved, what is compounded under physician guidance, and what is research-grade only and should not be self-administered. If you are considering peptide therapy in north Mississippi or anywhere else, the most important thing you can do is understand the regulatory and safety landscape before you understand the molecules.

If you have already done your reading and you are ready to talk through a personalized plan with a clinician, you can book a consultation at any of our clinics or call 877-665-6767. We see patients in Oxford, Olive Branch, and Corinth.

What Peptides Actually Are

Peptides are short chains of amino acids. By convention, "peptide" usually refers to a chain shorter than about 50 amino acids; longer chains start being called proteins, and by the time you get to insulin or growth hormone, you are clearly in protein territory. The line between "peptide" and "protein" is fuzzy, but the practical point is that peptides are small, biologically active molecules that work as signals.

Your body manufactures hundreds of peptides on its own. Insulin is a peptide. Glucagon is a peptide. Oxytocin, vasopressin, and growth hormone-releasing hormone are all peptides. Many of the hormones you have heard of are technically peptide hormones. The reason peptides have become a category of therapeutics is that we have learned how to synthesize them in a lab, modify them slightly to last longer in the bloodstream or bind more tightly to specific receptors, and use them to nudge the body's own signaling systems.

How Peptides Are Different From Hormones, Drugs, and Supplements

Patients often ask whether peptides are hormones, supplements, or pharmaceuticals. The honest answer is that they sit in a category of their own and often have one foot in each.

• Versus hormones: Some peptides are technically hormones (insulin, GHRH). Others are not hormones themselves but cause the release of hormones. The GHRH and GHRP families, for example, do not replace growth hormone; they tell the pituitary to release more of its own.
• Versus traditional drugs: A peptide is essentially a biologic, not a small molecule. They are usually injected because the digestive system breaks them down. Some, like the FDA-approved tesamorelin, are formal pharmaceuticals. Others are compounded under a physician's prescription.
• Versus supplements: Peptides are not dietary supplements. The "peptide" pills and powders sold on the supplement shelf are usually collagen fragments or whey-derived peptides with limited systemic activity. Therapeutic peptides used in clinics are prescription-only.

The key concept is signaling. A therapeutic peptide is rarely doing the work itself. It is binding to a receptor, triggering a cascade, and letting the body do what it already knows how to do. This is also why peptide therapy works best when the underlying biology is healthy enough to respond. We will return to that point throughout the article.

The 2024-2026 Regulatory Landscape

This is the section that most "peptide therapy" articles online either gloss over or get wrong. If you only read one section, read this one.

The FDA regulates peptides under several frameworks. A small number of peptides are FDA-approved drugs, manufactured by pharmaceutical companies and sold under brand names. Tesamorelin, marketed as Egrifta, is one example, approved for HIV-associated lipodystrophy. Sermorelin had a long history as an FDA-approved product before its commercial discontinuation, and is now used as a compounded preparation. Semaglutide and tirzepatide, while often discussed alongside peptides, are technically peptide-based drugs that are FDA-approved for diabetes and weight management.

Most of the peptides patients ask us about, however, are not FDA-approved finished drugs. They are bulk active pharmaceutical ingredients that licensed compounding pharmacies can prepare into patient-specific prescriptions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This is the same framework that allows a compounding pharmacy to prepare a custom-strength testosterone cream or a preservative-free injectable. The compounding pathway is legal, regulated, and is how the vast majority of clinically used peptides reach patients.

What changed between 2023 and 2026 is which substances are eligible for compounding. The FDA periodically reviews the bulk drug substances that 503A pharmacies can use and places some on its "Category 2" list, which restricts compounding due to significant safety risks. BPC-157 was the most prominent peptide affected. After agency review, BPC-157 was placed on Category 2, which means compounding pharmacies cannot routinely include it on their menus. Some peptides have been clarified as eligible, others have been formally restricted, and the practical result is that the menu of "easy to source legally" peptides is narrower in 2026 than it was in 2022.

Why this matters for patients:

• If a clinic is offering a peptide that the FDA has placed on Category 2, that should prompt questions. There are still pathways some physicians use, but they are not the routine compounding pathway, and the patient deserves a clear conversation.
• "Research-grade" peptides sold online are not legal for human use. Vials labeled "for research purposes only, not for human consumption" are sold by gray-market suppliers as a workaround. They are not held to pharmaceutical sterility, identity, or purity standards. We strongly counsel patients away from them.
• Some peptides remain routinely compoundable through licensed pharmacies in 2026. Sermorelin, ipamorelin, CJC-1295, and several others continue to be available through 503A pharmacies under physician prescription, subject to the same patient-specific medical necessity standards as any compound.
• FDA-approved peptide drugs (tesamorelin, semaglutide, tirzepatide, etc.) are unaffected by the compounding rule changes for their approved uses.

The core point: the regulatory landscape is dynamic. A responsible clinic in 2026 should be transparent with you about which category each recommended peptide falls into. If the answer is fuzzy, that is itself diagnostic of how the clinic is operating. At Impact Health, we work only with licensed compounding pharmacies, only on substances that the pharmacy can legally prepare under the current FDA guidance, and we update our protocols when the guidance updates. We will not prescribe a peptide simply because a patient asks for it if the legitimate sourcing pathway is closed. We will tell you why and discuss alternatives.

Healing and Repair: BPC-157 and TB-500

BPC-157 (body protective compound 157) and TB-500 (a synthetic fragment of thymosin beta-4) are the two peptides most associated with the "tissue healing" category. They are also the most discussed and, frankly, the most misunderstood. Online forums portray them as miracle cures for everything from torn rotator cuffs to inflammatory bowel disease. Reality is more nuanced.

How They Work

BPC-157 is a 15-amino-acid sequence derived from a protein found in human gastric juice. In animal models, it accelerates tendon, ligament, muscle, and gut tissue healing. The proposed mechanisms include upregulation of growth hormone receptors at the injury site, modulation of nitric oxide pathways, promotion of angiogenesis (new blood vessel formation in healing tissue), and modulation of inflammatory signaling.

TB-500 is the synthetic version of a region of thymosin beta-4, a naturally occurring peptide found in nearly every cell of the body. It promotes actin remodeling, which is the molecular machinery of cell migration. Practically, that means it helps cells get to where they need to be during tissue repair. It has been studied in cardiac repair, wound healing, and connective tissue injury models.

The Evidence Picture

There is a real body of preclinical (animal) evidence on both compounds. There is a much smaller body of human clinical trial evidence. Most of what is known about their use in humans comes from clinical experience reported by physicians and from small case series. That is an honest picture: not snake oil, not yet a fully validated clinical entity. Patients should hold both possibilities in mind and not be sold on either extreme.

Current Regulatory Status

BPC-157 was placed on the FDA's Category 2 list during the agency's 503A review. That status means that licensed compounding pharmacies cannot routinely include BPC-157 on their compounding menus. TB-500 is in a similar gray zone in 2026, with availability varying by pharmacy and by jurisdiction.

What that means practically: clinics that are still casually offering BPC-157 or TB-500 in 2026 should be asked how they are sourcing it. Some clinics use research products and have crossed an ethical and legal line. We do not. If you are reading this and a friend is on BPC-157 from an online "research peptide" vendor, please share this article with them.

Common Reported Protocols

Because both compounds are widely discussed online, patients often arrive with a specific protocol in mind, usually some form of daily subcutaneous BPC-157 with or without TB-500 over a four-to-eight-week course. We mention this not to validate it as a prescription we will write but because patients deserve to know what is being talked about. The historical clinical usage pattern in pre-2024 practice was lower-dose, time-limited, paired with the actual injury and not used as an open-ended supplement. Anyone doing this open-endedly, indefinitely, has wandered well outside the framework that produced whatever modest evidence base exists.

If The Evidence Excites You

If you are drawn to the healing and repair use case, the most clinically defensible 2026 conversation is about overall recovery optimization rather than a single peptide. That includes evaluating sleep, addressing low testosterone if present (see our TRT program), assessing baseline IGF-1, optimizing protein intake, considering targeted physical therapy and load management, and using FDA-approved or routinely compoundable adjuncts where appropriate. The healing the body does after a tendon injury is fundamentally a function of blood flow, mechanical loading, sleep, protein turnover, and inflammatory milieu. A peptide is at most a modulator of that environment. The environment itself is what mostly determines the outcome. We will tell you what we can responsibly prescribe and what we will not, and we will not make promises that the molecule cannot keep.

The GHRH/GHRP Family: Sermorelin, Ipamorelin, CJC-1295, and Tesamorelin

This is the category where most legitimate, ongoing peptide therapy in 2026 happens, and it is the category where the science is most mature. The GHRH (growth hormone-releasing hormone) and GHRP (growth hormone-releasing peptide) compounds work together to nudge the pituitary gland to release more of the body's own growth hormone in pulses that mimic natural physiology.

Why Pulsatile GH Matters

Growth hormone is not meant to be at a steady level in your bloodstream. It is supposed to surge in pulses, particularly during deep sleep and after intense exercise. Direct injection of recombinant human growth hormone (HGH) creates an unphysiological steady-state level, suppresses the body's own GH axis through negative feedback, and is associated with side effects like edema, joint pain, carpal tunnel symptoms, insulin resistance, and a higher long-term risk profile. Direct HGH is also a controlled substance, restricted by federal law to specific approved indications.

The GHRH/GHRP approach is fundamentally different. Instead of replacing growth hormone, you are sending a signal to the pituitary, asking it to do more of what it already does. The body retains its own feedback loops. The pulses look like natural pulses. The total daily growth hormone exposure is higher than baseline, but lower and more physiologic than direct HGH injection. This is why we, and the broader integrative medicine community, almost always prefer the GHRH/GHRP family over recombinant HGH in the patients we are trying to help.

Sermorelin

Sermorelin is a synthetic analogue of the first 29 amino acids of natural GHRH. It binds to GHRH receptors on the pituitary and stimulates GH release. Historically it was an FDA-approved drug; the brand-name product was discontinued, and sermorelin is now provided through compounding pharmacies. It has a short half-life, so it is typically dosed at night to align with the body's natural overnight GH pulse. Patients tend to report improvements in sleep quality, recovery, and over months, body composition. Sermorelin has the longest clinical track record of the family and is often the first peptide we consider for someone newer to this category.

Ipamorelin

Ipamorelin is a selective GHRP. It binds to the ghrelin receptor and stimulates GH release without significantly affecting cortisol, prolactin, or appetite, which has historically been a problem with older GHRPs. The selectivity is the reason it has become the workhorse of the modern peptide protocol. Ipamorelin pairs well with a GHRH like sermorelin or CJC-1295, because the two mechanisms are complementary: GHRH increases the size of each pulse, while the GHRP increases pulse frequency.

CJC-1295

CJC-1295 is a longer-acting GHRH analogue. It comes in two forms in the literature: with DAC (drug affinity complex) and without DAC. The without-DAC form, often called modified GRF 1-29 or CJC-1295 no-DAC, has a half-life of around 30 minutes and produces clean nightly pulses. The with-DAC form has a half-life of days, producing steadier elevations. Most clinicians prefer the no-DAC form because it preserves pulsatility, which is the whole point of using GHRH in the first place. CJC-1295 is commonly stacked with ipamorelin in a single nightly subcutaneous injection.

Tesamorelin

Tesamorelin (brand name Egrifta) is the most rigorously studied GHRH analogue. It is FDA-approved for HIV-associated lipodystrophy, the visceral fat accumulation seen in patients on certain antiretroviral regimens. The clinical trials demonstrated meaningful reductions in visceral adipose tissue with acceptable safety. Outside its approved indication, tesamorelin is sometimes considered for patients with significant visceral adiposity. Because it is an FDA-approved finished drug, the cost is materially higher than compounded sermorelin or ipamorelin/CJC-1295 stacks, and it is generally reserved for cases where its specific evidence base matters.

Comparison Summary

• Sermorelin: GHRH analogue, short half-life, longest clinical track record, often first-line.
• Ipamorelin: Selective GHRP, no significant cortisol or appetite effects, almost always paired with a GHRH.
• CJC-1295 (no-DAC): Longer GHRH analogue, paired with ipamorelin in many modern protocols.
• Tesamorelin: FDA-approved GHRH analogue, strongest evidence base, used selectively due to cost and indication specificity.

What To Realistically Expect

Patients on a well-designed GHRH/GHRP protocol typically notice improved sleep quality and recovery within the first few weeks. The sleep change is often the most striking early signal, with patients reporting deeper, more restorative sleep and clearer mornings. Body composition shifts (fat loss, lean mass preservation, modest lean mass gain when paired with training) tend to emerge over three to six months. Skin quality, hair quality, and the catch-all bucket of "vitality" are softer signals that often improve over the same window but are harder to attribute precisely. IGF-1 levels, which we measure as a downstream marker of GH activity, generally rise into the upper-normal range, which is the goal. We do not chase supraphysiologic IGF-1 levels. The safety margin of the approach comes from staying within physiologic ranges, and chasing higher numbers gives back the safety advantage that made you choose this approach in the first place. Patients who arrive expecting visible "transformation" results in four weeks are gently recalibrated. The signal these compounds produce is real but cumulative and is amplified or blunted by the rest of the picture: training, food, sleep, alcohol, stress.

Who Is and Is Not a Candidate

Good candidates: adults over 30 with documented IGF-1 in the lower half of the reference range, generally healthy, with reasonable sleep and training habits, who have addressed the more proximal levers (hormone optimization where indicated, sleep, nutrition) and want to add a layer. Poor candidates: anyone with active or recent malignancy, anyone with uncontrolled diabetes or significant prediabetes without first addressing it, anyone with active proliferative retinopathy, pregnant or breastfeeding patients, adolescents, and competitive athletes subject to drug testing. Borderline candidates: patients with significant cardiovascular disease (we coordinate with cardiology), patients on multiple psychiatric medications (we screen carefully for interactions and confounders), and patients whose primary issue is actually mood, anxiety, or trauma that has been mistaken for a physical complaint.

Body Composition: AOD-9604 and MOTS-c

The body composition category has been reshaped by the GLP-1 revolution. Five years ago, peptides like AOD-9604 were marketed for fat loss in a market that did not have semaglutide or tirzepatide as off-the-shelf options. Today, GLP-1 medications such as semaglutide and tirzepatide have such a dominant evidence base for clinically significant fat loss that the older fat-loss peptides occupy a much smaller niche.

AOD-9604

AOD-9604 is a fragment of the C-terminus of human growth hormone, specifically the region thought to be responsible for the fat-mobilizing effect of GH without the growth-promoting effects. Early animal data was promising. Human data has been mixed, with some studies failing to show a clinically meaningful weight-loss signal versus placebo. Its place in 2026 is essentially niche. It is not a substitute for a GLP-1 in someone who needs significant weight loss, and it is not commonly part of our protocols.

MOTS-c

MOTS-c is a mitochondria-derived peptide encoded within mitochondrial DNA. It plays a role in metabolic homeostasis and exercise capacity in animal models. It has captured attention as a "longevity" or "metabolic" peptide. Human clinical data is limited. Like several research-grade peptides, its availability through legitimate compounding pathways is constrained, and clinicians vary widely in whether they will prescribe it. We are conservative here.

Where Peptides Fit Alongside GLP-1s

The honest framing for patients in 2026 is that if your goal is meaningful fat loss, the GLP-1 family is the evidence-based first move, sometimes with adjunctive lifestyle support and resistance training. Peptide therapy in this domain is more relevant for body recomposition (preserving lean mass during a GLP-1 fat-loss phase, supporting recovery, supporting visceral fat reduction) than as a stand-alone fat-loss tool. The GHRH/GHRP family pairs well with a GLP-1 program for exactly this reason. See our weight loss program for how we integrate these.

Sleep and Recovery: DSIP and Epitalon

This category requires careful framing.

DSIP

DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide isolated from rabbit cerebral venous blood during sleep in research dating to the 1970s. The name promises more than the evidence delivers. Subsequent research found that DSIP's effects on human sleep architecture in controlled studies have been modest and inconsistent. It is not a sleep aid in the clinical sense. It is a research peptide with limited human data, and we do not consider it a routine clinical option.

Epitalon

Epitalon is a four-amino-acid peptide developed in Russian gerontology research. The published longevity claims rest largely on a research tradition that has not been independently replicated to the standards used in U.S. and Western European clinical trials. Telomere-related claims are biologically interesting but mechanistically tenuous in vivo. Epitalon falls firmly into research-grade territory in 2026. We are upfront with patients that we do not have a protocol for it that we would call clinically defensible.

The Honest Framing

Sleep and recovery are real clinical issues. Peptides are not the right first answer. Optimizing sleep hygiene, addressing untreated obstructive sleep apnea, treating anxiety or depression where present, and correcting hormone imbalances (testosterone, estradiol, thyroid, cortisol patterns) will move sleep further than any peptide on the current research-grade list. The GHRH/GHRP family, when used at night, has well-documented sleep-quality benefits, which is why it is the peptide we usually reach for when sleep is part of the picture. We have had patients arrive convinced they need DSIP for poor sleep who turned out to have moderate obstructive sleep apnea on a sleep study; the right intervention there was a CPAP, not a peptide, and once their apnea was treated their other complaints largely resolved.

Cognitive: Selank and Semax

Selank and Semax are short peptides developed in Russian neuroscience research. They are derivatives of, respectively, tuftsin (an immunomodulatory tetrapeptide) and ACTH (4-7) regions. Both have been studied for nootropic, anti-anxiety, and neuroprotective effects, primarily in Russian-language literature.

The U.S. regulatory status of selank and semax is research-grade. They are not FDA-approved. They are not routinely compounded by U.S. licensed pharmacies. Patients who pursue them in the U.S. usually do so via the gray-market online vendors we strongly advise against. The honest answer for cognitive optimization in 2026 in our practice is: address underlying drivers (sleep, hormones, blood sugar, micronutrient status, inflammation, mood), use FDA-approved tools when indicated, and recognize that selank and semax are interesting research compounds without a defensible clinical pathway in our setting.

Immune: Thymosin Alpha-1

Thymosin alpha-1 is the strongest evidence-base peptide in the immune category. It is a 28-amino-acid peptide produced naturally by the thymus gland. Its mechanism of action involves modulation of dendritic cells, T-cell maturation, and natural killer cell function. There is a meaningful body of research and international clinical use, including in chronic viral hepatitis and as an adjunct in some oncology and immune-deficiency settings. In some countries, thymosin alpha-1 is an approved drug; in the U.S., it has been used through compounding pathways.

Thymosin alpha-1 is most often considered for patients with chronic viral burdens, post-infectious recovery, immune dysregulation, or as an adjunct in certain oncology settings under physician supervision. It is not a routine peptide for healthy people seeking general "immune support." When we use it, we use it for a specific indication, with monitoring, and time-limited. The post-infectious recovery use case became more prominent during and after the COVID era, with some clinicians using thymosin alpha-1 in patients with prolonged post-viral fatigue and immune dysregulation. The evidence there is still developing, and we treat it as an active area where careful patient selection matters more than the peptide itself.

The Pre-Treatment Workup

Walking into a clinic and walking out with a peptide prescription on the first visit is a red flag, not a feature. The workup matters as much as the molecule.

Comprehensive Lab Panel

For any patient considering peptide therapy, particularly the GHRH/GHRP family, we run:

• Complete metabolic panel and complete blood count
• Comprehensive lipid panel
• Hemoglobin A1c and fasting insulin (GH-class peptides can affect insulin sensitivity)
• Total and free testosterone, SHBG, estradiol
• TSH, free T4, free T3, reverse T3 if indicated
• IGF-1 (the downstream marker we will track)
• DHEA-sulfate
• High-sensitivity CRP
• Vitamin D, B12, ferritin
• PSA in men over 40 before any GH-class therapy

The reason for this depth: peptide therapy is not the first move for most issues. If a man comes in asking for ipamorelin/CJC because he is fatigued, has poor recovery, and is putting on midsection weight, his testosterone is going to tell us a lot. If his free T is in single digits, the right first conversation is about testosterone optimization, not peptides. If a woman comes in for similar reasons and her thyroid panel is decompensated, we treat that first. Many of the symptoms peptides are marketed for are actually symptoms of more proximal issues.

You can see what is included in our standard panels on the lab panels page.

Body Composition Baseline

If you cannot measure it, you cannot manage it. We use 3D body composition scanning at our clinics for objective baseline and follow-up data. Scale weight does not capture what peptide therapy is actually doing. See body composition analysis for how this fits in.

Lifestyle Review

Sleep duration and quality, alcohol intake, training status, protein intake, stress load, and medication list. A patient sleeping six hours, drinking five nights per week, and not training is not a good candidate for peptide therapy in the literal sense that the therapy will not work the way we want it to. The signal we are asking the body to amplify is partly built from those inputs.

Symptom Inventory

Documented baseline symptom scoring. Six months in, "I feel a little better" is hard to interpret. A specific symptom inventory at baseline gives both you and us a clear way to know whether the protocol is working.

Injection Technique and Patient Education

Most therapeutic peptides are injected. A small number have nasal or oral formulations, but the systemic bioavailability is generally lower and the dosing less reliable. For the GHRH/GHRP family, subcutaneous injection is standard.

Subcutaneous Versus Intramuscular

Subcutaneous (under the skin) is the standard route for the peptides we prescribe. The needles are short (typically 5/16-inch, 29 to 31 gauge insulin syringes) and the technique is similar to insulin injection. The abdomen, the upper outer thigh, and the upper outer buttock are common sites. Rotation between sites prevents lipoatrophy and irritation. Intramuscular injection is rarely required for this peptide family.

Reconstitution

Many peptides are dispensed as a lyophilized (freeze-dried) powder in a vial. The patient or clinic reconstitutes the powder with bacteriostatic water before use. The reconstitution step matters. Adding water too forcefully can shear the peptide. Storing the reconstituted vial improperly can cause loss of potency. We provide written and in-person instructions and the first reconstitution is usually done with us.

Storage

Lyophilized vials are stable at room temperature for shipping and short-term storage. Once reconstituted, peptides should be refrigerated. Most reconstituted peptides are stable for several weeks refrigerated, though specifics vary by molecule. Do not freeze reconstituted vials.

Sharps Disposal

Used insulin syringes go into a sharps container, not the household trash. We provide containers and instructions for safe disposal. Pharmacy take-back programs exist in our area.

What "Self-Injection" Really Looks Like

Patients are sometimes surprised that the practical experience is similar to a daily insulin injection. The needles are small enough that most patients describe them as a pinch. Within two or three days of doing it, the procedure becomes a routine part of the morning or evening, not an event. The gating concern for almost every patient is anticipatory anxiety, not the actual pain of the injection. We have walked nervous first-timers through it dozens of times. The pattern is reliable: the second injection is easier than the first, the seventh is easier than the second, and within two weeks most patients describe the process as "barely thinking about it." If genuine needle phobia is a barrier, we discuss it openly. There are options including a topical numbing agent, slower needle advancement, and in rare cases nasal-route alternatives where they exist for the molecule in question.

Common Mistakes

• Reusing needles. Insulin syringes are single-use. Reusing dulls the needle and increases infection risk.
• Injecting cold. A vial straight from the refrigerator is more uncomfortable; let it warm to room temperature for a minute or two.
• Same-spot injection. Always rotate. Even within the abdomen, vary the quadrant.
• Skipping the alcohol pad. Both the vial top and the injection site get a quick wipe.
• Drawing too vigorously. Slow draws preserve the peptide.

Stacking Peptides With TRT, HRT, GLP-1, and NAD+

Peptide therapy rarely happens in isolation in our practice. Patients usually come to us with a constellation of goals, and the right plan is integrated.

With TRT or HRT

Testosterone optimization in men or hormone replacement in women is often the foundation. Hormone-deficient patients respond to peptides differently than hormone-replete patients. Many of the symptoms patients hope peptides will solve (fatigue, recovery, body composition, libido) are more efficiently addressed by correcting the underlying hormone deficiency first, then adding a peptide layer if and when there is residual room to optimize. See TRT and HRT.

With GLP-1 Weight Loss

This is one of the most clinically interesting combinations in 2026. GLP-1 medications produce significant fat loss but, like any aggressive weight loss intervention, can take some lean mass with it. A nighttime GHRH/GHRP stack supports lean mass preservation and recovery during the GLP-1 phase. Resistance training and adequate protein intake remain the two most important interventions; the peptide adds a third lever.

With NAD+ Therapy

NAD+ supports cellular energy and mitochondrial function. Patients on a GHRH/GHRP protocol who are also doing NAD+ therapy often describe complementary effects: peptides improving sleep architecture and recovery, NAD+ supporting daytime energy and cognitive endurance. There is no formal pharmacological interaction; they operate on different systems.

With Food Sensitivity Work

Recovery, inflammation, and gut health intersect more than most patients realize. Several of the patients who arrive asking about BPC-157 for "gut healing" actually have undiagnosed food sensitivities driving their symptoms. Food allergy testing can resurface a plan that peptide therapy alone would not have solved.

Cycling and Timing Principles

Two principles guide modern peptide protocols: pulses, not floods, and cycles, not endless courses.

Why Pulses

The body's own GH and many other peptide systems work in pulses. Continuous high-level signaling causes receptor desensitization. The GHRH/GHRP class respects this by producing brief, physiologic surges (typically once daily, at night) rather than constant exposure. Patients sometimes ask whether twice or three times daily dosing would amplify results. Almost universally the answer is no, because the receptors do not respond linearly. Smaller, well-timed pulses outperform constant exposure.

Why Cycles

Most peptide protocols in our practice run in defined cycles: a treatment phase of three to six months, a re-evaluation, and often a planned break or a step-down dose. Cycling accomplishes several things. It limits cumulative exposure when long-term safety data is incomplete. It re-sensitizes receptors. It forces a reassessment, so patients are not staying on therapy because of inertia rather than continued benefit.

Time of Day

For the GHRH/GHRP family, evening dosing aligns with the natural overnight GH pulse and avoids interference with daytime insulin sensitivity. We typically advise injection 30 to 60 minutes before bed, on an empty stomach (food, particularly carbohydrate, can blunt the GH response).

What We Will NOT Prescribe and Why

This section is the patient-safety lecture. We do not apologize for it.

Peptides Without a Clinical Use Case

If a patient asks for a peptide because they read about it on a forum and there is no defensible mechanism or evidence base for their indication, we say no. Peptides that fit this category in 2026 include several research-grade compounds being marketed online for benefits that the literature does not support. Wanting a treatment is not the same as needing a treatment.

Research-Grade Products From Non-Licensed Sources

Vials labeled "for research use only, not for human consumption" sold by online "peptide companies" are a real and growing patient-safety problem. They are not pharmaceuticals. They are not held to USP sterility, identity, or potency standards. Several published case reports describe contamination, mislabeling, and unexpected biological activity in products from these vendors. We will not prescribe alongside, validate, or "monitor" patients who are using research peptides. We will, however, have a frank conversation with you about what you are doing, what you are risking, and what legitimate alternatives exist.

Online "Peptide Vendors" Generally

If a website ships you a peptide without a prescription, without a licensed pharmacist, and without a clinical evaluation, that website is not a pharmacy. Whatever else it might be, it is not part of the regulated medical supply chain. Patients sometimes ask whether they can bring vials they ordered online to us and have us "supervise" their use. The answer is no. We cannot vouch for what is in that vial. Doing so would put us, and you, in an indefensible position.

Peptides Restricted by FDA Category 2

If the FDA has determined, after formal review, that a substance carries significant safety concerns sufficient to restrict compounding, we respect that determination. We will explain it to you. We will discuss alternatives. We will not work around it.

Indications That Do Not Make Medical Sense

"I want to try peptides because I'm bored of my training plateau" is not a medical indication. We are happy to have a conversation about what is actually going on, what the realistic levers are, and whether peptides have a place. Sometimes they do. Often, the answer is that sleep, training programming, nutrition, or hormone optimization will move the needle further.

Side Effects and Monitoring

Peptides are not benign. The reason we use the GHRH/GHRP family at physiologic-mimicking doses is precisely to minimize side effects. Even so, several deserve discussion.

Injection-Site Reactions

Local redness, mild swelling, or transient bruising are the most common findings. Site rotation, proper technique, and bringing the vial to room temperature before injecting (without warming in the microwave) reduce these.

Water Retention

GH-class effects can include mild fluid retention, particularly in the first weeks. Patients sometimes notice puffiness around the eyes or hands. This usually resolves with continued use or with a small dose adjustment. Significant or persistent edema is a reason to reduce the dose or pause.

Joint Discomfort and Carpal Tunnel-Like Symptoms

Both are dose-related GH-class effects, much more common with direct HGH than with the GHRH/GHRP approach, but possible. They are reversible and dose-responsive. We start low and titrate up, and we listen when patients report them.

Blood-Sugar Effects

GH and IGF-1 affect insulin sensitivity. Most patients without metabolic disease tolerate peptide therapy without measurable changes in fasting glucose or A1c. Patients with prediabetes or diabetes need careful monitoring. We track A1c and fasting glucose at baseline and at follow-ups.

Lab Follow-Up Schedule

• Baseline: full panel as described
• 4 weeks: targeted reassessment, dose adjustments
• 3 months: IGF-1, A1c, comprehensive metabolic panel, symptom inventory
• 6 months: full repeat panel, body composition, decision on continuation, dose, or cycle break
• Ongoing: every 3 to 6 months as long as therapy continues

Reasons To Stop

Persistent edema, persistent paresthesias, rising fasting glucose or A1c, IGF-1 above the upper-normal range, and any new finding that has not been previously evaluated. Stopping a peptide is not a failure. It is an appropriate response to the data.

Costs and the Cash-Pay Model

Peptide therapy is a cash-pay service. Insurance does not generally cover it, with rare exceptions for specific FDA-approved indications. We are upfront about that.

What patients pay for in a legitimate program: the clinical evaluation, the prescriber's time, the labs, the compounding pharmacy fees, the actual peptide, the follow-up visits, and the supplies (syringes, alcohol pads, sharps container). The actual peptide is often a smaller portion of total cost than patients expect. The clinical infrastructure is the larger portion, and it is also the part that distinguishes a legitimate program from a research-vial purchase.

We do not publish dollar amounts in articles like this because pricing depends on the specific peptide, dose, source, and bundle. A one-on-one consult is the right place for that conversation. What we can tell you in advance: a transparent quote will be itemized, will explain what is and is not included, and will not use bait-and-switch pricing. If a clinic is reluctant to itemize, that itself is information.

The Impact Health Protocol

Every patient walks the same path, even though the destination differs.

1. Initial consultation. An hour-long visit (in person or telehealth where appropriate) covering history, goals, prior workups, current medications, and what you have already tried. This is a no-pressure conversation. If we do not think peptide therapy is the right tool for what you are trying to solve, we will tell you.
2. Comprehensive lab panel. The panel above. We draw locally or send patients to a partner lab. Results return in five to ten business days.
3. Lab review and personalized stack. A focused follow-up visit to review the panel, discuss the proposed protocol, and finalize the prescription. This is the visit where we explain regulatory categories for each peptide we are recommending, the specific compounding pharmacy, the dose, the cycle length, and the cost.
4. Onboarding and first injection. Reconstitution, technique demonstration, and the first injection done with us. Most patients leave the clinic having already done it once.
5. 4-week check-in. Tolerance, side effects, early subjective changes, and any dose adjustments.
6. Quarterly re-evaluation. Lab repeat, body composition repeat, symptom inventory, and a structured decision: continue, adjust, or cycle off.

Peptide therapy is available at our Oxford, Olive Branch, and Corinth locations. You can see all three on the locations page. To start, book a consultation or call 877-665-6767. If you want to read more first, the how it works page walks through what to expect at a first visit, and the main blog has articles on adjacent topics.

Composite Scenarios

The following scenarios are composites built from typical patient patterns. They are not specific patients and they are not predictions of what your protocol would look like.

Scenario One: Recovery From Repeated Soft-Tissue Injury

A 42-year-old recreational athlete had been training consistently for two decades and over the past three years had accumulated a recurring rotator cuff strain, an Achilles flare, and persistent low-grade hip pain. Conservative orthopedic care, physical therapy, and a cortisone injection had each helped briefly. He arrived asking specifically for BPC-157 because of what he had read online.

The honest 2026 conversation: the regulatory status of BPC-157 made the easy answer he was hoping for unavailable. The fuller workup found total testosterone in the low 300s, IGF-1 at the bottom of the reference range, vitamin D at 22, and a sleep score consistent with mild but untreated obstructive sleep apnea (which a sleep study later confirmed). The plan was layered: a sleep study referral and CPAP, vitamin D repletion, an on-label evaluation for testosterone optimization, and a nightly GHRH/GHRP stack for three months with an emphasis on sleep architecture and recovery support, alongside a structured return-to-training plan with his physical therapist. Six months later, three of the four chronic complaints were gone. The peptide piece was real but it was not the whole story, and a single-peptide answer would have missed the rest.

Scenario Two: Midlife Body Composition

A 51-year-old executive had been working out four to five days a week for years but had watched her body composition drift. Belly weight she had never carried before, lean mass that felt diminished, and recovery between workouts that had stretched from a day to several days. She came in interested in "the peptides everyone is talking about."

Her labs showed a perimenopausal pattern with estradiol fluctuating, a low-normal free T, sluggish thyroid markers, and IGF-1 in the lower third of the range. The plan: bioidentical hormone replacement appropriate to her stage, thyroid optimization, structured resistance training, dietary protein increase, and a six-month nightly sermorelin/ipamorelin stack. Her three-month and six-month body composition scans documented visceral fat reduction and lean mass preservation. The hormone work and the training did the bulk of the lifting; the peptide added a measurable layer on top.

Scenario Three: Longevity-Oriented Stack

A 58-year-old engineer with no acute issues but a strong family history of cardiovascular disease and Alzheimer's was looking for a structured prevention strategy. He had read widely and arrived with a long list of compounds he wanted to try.

The plan focused on what we could justify: a comprehensive cardiometabolic workup, lipid optimization with cardiology coordination, sleep evaluation, structured training, and a nightly low-dose GHRH/GHRP stack with quarterly IGF-1 monitoring kept in the upper-normal range, not above. We declined to write for several of the items on his list because the evidence base or the regulatory pathway did not support it. He was initially disappointed and ultimately appreciated the discipline. His follow-up labs at six and twelve months were in his targets, his training had progressed, and the conversation has been about extending the protocol, not abandoning it.

Frequently Asked Questions

1. Are peptides legal?

It depends on the peptide and the source. FDA-approved peptide drugs (tesamorelin, semaglutide, tirzepatide) are legal pharmaceuticals when prescribed for approved indications. Peptides compounded by licensed 503A pharmacies under physician prescription, on substances eligible for compounding under current FDA guidance, are legal. Research-grade peptides sold by online vendors as "not for human consumption" exist in a gray-to-illegal zone and are not legal for human therapeutic use. The category of the peptide and the source matter as much as the molecule itself.

2. Are peptides FDA-approved?

Some are; most of the popular ones are not. Tesamorelin, semaglutide, and tirzepatide are FDA-approved finished drugs. Sermorelin, ipamorelin, CJC-1295, and similar peptides are not FDA-approved finished drugs but are commonly compounded by licensed pharmacies under physician prescription, subject to current FDA guidance on which substances are eligible. BPC-157, TB-500, MOTS-c, selank, semax, and many others are not FDA-approved and are not routinely compoundable in 2026.

3. Can I order peptides online and bring them to you to monitor?

No. We cannot validate the identity, sterility, potency, or purity of products from non-licensed sources. Monitoring or "supervising" the use of products from those vendors would put both you and us in an indefensible position. We will, however, have a frank conversation about what you are doing, the risks, and the legitimate alternatives.

4. Do I have to inject myself?

For the GHRH/GHRP family and most clinically used peptides, yes. Subcutaneous injection is the standard route and is similar in technique to insulin injection. The needles are very small and most patients describe the sensation as a pinch. We teach the technique and do the first injection with you. Some peptides have nasal or oral formulations, but they are generally less reliable, less potent, or both.

5. Will I lose muscle if I stop?

Stopping a GHRH/GHRP protocol returns your GH and IGF-1 levels toward your pre-treatment baseline. Some of the body composition gains that depended on elevated IGF-1 will partly regress over time, especially without continued resistance training and adequate protein. The gains that depended on the training itself will persist. The honest framing is that peptide therapy is a layer; if you remove the layer, you keep what the foundation was holding up but lose what the layer was adding.

6. Can I cycle on and off?

Yes, and we usually recommend it. Most of our protocols run three to six months on, then a re-evaluation, often with a planned break or step-down. Cycling helps preserve receptor sensitivity, limits cumulative exposure when long-term data is incomplete, and forces a structured reassessment.

7. Can women do peptide therapy?

Yes. The GHRH/GHRP family is appropriate in women as in men, with similar physiology and similar safety considerations. Peptide therapy is often complementary to hormone work in perimenopausal and post-menopausal women. Several of our most successful peptide cases are women. See HRT for the broader hormonal context.

8. What about athletes who get drug-tested?

Most of the peptides in this article (the GHRH/GHRP family, BPC-157, TB-500, AOD-9604, MOTS-c, and others) are on the World Anti-Doping Agency prohibited list or its equivalents in most professional sports. Competitive athletes subject to testing should not use these compounds. We will tell you so before any prescription, and we are not a clinic that helps athletes circumvent testing.

9. Are these safe long-term?

The honest answer is that long-term data on most clinically used peptides is more limited than for, say, testosterone replacement or thyroid replacement, which have decades of follow-up. The GHRH/GHRP family has the strongest accumulated experience and reassuring physiologic logic. Tesamorelin, as an FDA-approved drug, has trial-grade safety data within its indication. For other peptides, the long-term data is still being built. Cycling, monitoring, and staying within physiologic ranges are how we manage that uncertainty.

10. What's the difference between BPC-157 and TB-500?

Both are associated with tissue healing in the literature. BPC-157 is derived from a gastric protein and has been studied in tendon, ligament, gut, and muscle injury models. TB-500 is a fragment of thymosin beta-4 and works through actin remodeling and cell migration pathways. In animal models, the two have somewhat complementary mechanisms, which is why they are sometimes discussed together. In 2026, both have constrained legitimate availability, and we would have a careful conversation before prescribing either.

11. Can I do peptide therapy alongside GLP-1 weight loss?

In many cases, yes, and this is one of the most clinically interesting combinations of the current era. A nightly GHRH/GHRP stack supports lean mass preservation and recovery during a GLP-1 fat-loss phase. We coordinate the two carefully, particularly around blood-sugar effects and lab monitoring. See weight loss for context.

12. What about teenagers?

We do not prescribe peptide therapy for adolescents. The growth axis in a developing teenager is doing exactly what it is supposed to do, and exogenous manipulation is not appropriate outside of specific endocrinologic disease managed by a pediatric endocrinologist. Teenage athletes whose parents bring them to us asking for "performance peptides" leave with a different conversation. So do their parents.

Closing Thoughts and Next Steps

Peptide therapy in 2026 is a more interesting field than it was even three years ago, and at the same time a more carefully bounded field than it was five years ago. The molecules with the strongest evidence and clearest legitimate sourcing pathways, the GHRH/GHRP family chief among them, are genuinely useful tools for the right patient and the right indication. The molecules that occupy the gray edge of the regulatory framework deserve more skepticism than the internet usually applies to them. The molecules sold by online vendors as "research only" deserve none of your money and none of your body.

If you are considering peptide therapy in north Mississippi, our standing offer is straightforward: come in for a consultation, get the workup, and let us tell you what your situation actually calls for. Sometimes that is a peptide protocol. Sometimes it is a hormone optimization protocol. Sometimes it is a GLP-1 program. Sometimes it is sleep, training, and nutrition with no prescription at all. We have all of those tools and we use the one that fits.

To get started, book a consultation at the Oxford, Olive Branch, or Corinth location, or call 877-665-6767 to speak with our team. If you would rather email first, the contact page has the form. The main peptide therapy page has program details, and adjacent services like TRT, HRT, NAD+ therapy, and our lab panels are all part of the integrated workup we use to design a plan that actually fits your goals.

Medical Disclaimer

This article is for general educational and informational purposes only and is not medical advice. It does not establish a clinician-patient relationship and is not a substitute for individualized evaluation by a licensed medical professional. Peptide therapy involves the use of compounds with varying regulatory status; some discussed here are FDA-approved drugs, others are compounded preparations under physician prescription, and others are research-grade compounds without an established legitimate clinical pathway in the United States. Regulatory categories and FDA guidance change over time, including during the 2024 to 2026 period this article references. Any decision to begin, modify, or discontinue any therapy should be made in consultation with a qualified clinician familiar with your full medical history. Do not purchase, possess, or self-administer peptides from non-licensed online vendors or "research peptide" suppliers. Products sold as "for research purposes only, not for human consumption" are not pharmaceuticals, are not held to USP sterility, identity, or purity standards, and have been associated in published case reports with contamination, mislabeling, and unexpected biological activity. If you are an athlete subject to anti-doping testing, be aware that many peptides discussed in this article are prohibited under WADA and most professional sport rules. If you are pregnant, breastfeeding, an adolescent, or have a history of malignancy, additional precautions apply and several of the protocols described are contraindicated. Individual results vary; nothing in this article should be read as a promise or guarantee of any specific outcome.